Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Aclaris Therapeutics, Inc. (ACRS) is a Biotechnology company based in US with a market capitalization of $686.2M. Revenue declined 58.2% year-over-year and free cash flow was negative at -$47.2M. This page tracks ACRS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 61 employees · IPO Oct 6, 2015
Valuation
Valuation & price
$4.80as of May 15, 2026· -13.7% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
6.66
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$686.2M
Market cap
-58.2%
Revenue growth (YoY)
73.3%
Gross margin
-$47.2M
Free cash flow (USD)
-$88.6M
Net debt
Net cash position
58.7%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
1
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 7, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Aclaris Therapeutics, Inc.'s market cap?
Aclaris Therapeutics, Inc. (ACRS) has a market capitalization of $686.2M.
What is ACRS's P/E ratio?
A meaningful P/E ratio is not available for ACRS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is ACRS's price-to-book (P/B) ratio?
ACRS trades at 6.66 times book value per share.
Are insiders buying ACRS stock?
SEC Form 4 filings show no open-market insider buys at Aclaris Therapeutics, Inc. in the last 90 days (1 sell).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.